Keros Therapeutics reports Q2 EPS ($1.27), consensus ($1.34)

“We are excited to share our initial development plans for KER-065-an activin receptor ligand trap that is designed to increase skeletal muscle and bone mass, increase fat metabolism and reduce fibrosis-in Duchenne muscular dystrophy, a debilitating disease with a serious unmet need, and look forward to moving this important program into the clinic in the first quarter of 2024,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. “As highlighted by the progression of KER-065 and the initiation of our Phase 2 clinical trial of KER-012 in patients with pulmonary arterial hypertension, we continue to execute on our strategy of developing our pipeline of differentiated assets designed to harness the powerful biology of the TGF-ss family of proteins.”